{"id":704738,"date":"2024-07-01T11:18:01","date_gmt":"2024-07-01T11:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=704738"},"modified":"2024-07-01T11:18:01","modified_gmt":"2024-07-01T11:18:01","slug":"cmet-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cmet-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight_704738.html","title":{"rendered":"C-MET Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1719826517.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"C-MET Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1719826517.jpeg\" alt=\"C-MET Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;&ldquo;<strong>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight 2024&rdquo;<\/strong>&nbsp;report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the C-MET Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Explore our latest breakthroughs in C-MET Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">C-MET Non-Small Cell Lung Cancer Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the C-MET Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>June 2024:- AbbVie<\/strong>&#8211; A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced\/Metastatic Non-Squamous Non-Small Cell Lung Cancer.<\/li>\n<li><strong>May 2024: Apollomics Inc.-<\/strong> Phase 1 \/ 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.<\/li>\n<li>DelveInsight&rsquo;s C-MET Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for C-MET Non-Small Cell Lung Cancer treatment.<\/li>\n<li>The leading C-MET Non-Small Cell Lung Cancer Companies such as <em><strong>Novartis, Apollomics Inc., Abbvie, Janssen Research and Development<\/strong><\/em>, and others.<\/li>\n<li>Promising C-MET Non-Small Cell Lung Cancer Therapies such as <em><strong>Glumetinib, Telisotuzumab vedotin, Tepotinib, APL-101 Oral Capsules, MCLA-129, Osimertinib, PLB1001<\/strong><\/em>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay informed about the cutting-edge advancements in C-MET Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">C-MET Non-Small Cell Lung Cancer Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>C-MET Non-Small Cell Lung Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>EGF-816 (Nazartinib): Novartis Oncology<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Novarti&rsquo;s lead drug candidate, EGF-816 (Nazartinib), is small molecule in combination with INC280 is in development for the treatment of non-small cell lung cancer. Clinical trials data demonstrated that EGF-816 (Nazartinib) for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) has beneficial effects. The drug is a new molecule which is an epidermal growth factor receptor antagonist that blocks the function of protein EGFR.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>APL 101 (Bozitinib): Appolomics Inc.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Apollomics drug APL 101 (Bozitinib) is an orally administered small molecule currently being evaluated for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and has demonstrated good safety and efficacy profile in phase II trials. APL 101 (Bozitinib) is an anti-neoplastics which inhibits the C-met protein.<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about C-MET Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking C-MET Non-Small Cell Lung Cancer Research and development projects @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">C-MET Non-Small Cell Lung Cancer Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Subcutaneous<\/li>\n<li>Intravenous<\/li>\n<li>Oral<\/li>\n<li>Intramuscular<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>C-MET Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Small molecules<\/li>\n<li>Natural metabolites<\/li>\n<li>Monoclonal antibodies<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover the latest advancements in C-MET Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we&#8217;re transforming the future of oncology @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">C-MET Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the C-MET Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>C-MET Non-Small Cell Lung Cancer Companies- Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others.<\/li>\n<li>C-MET Non-Small Cell Lung Cancer Therapies- Glumetinib, Telisotuzumab vedotin, Tepotinib, APL-101 Oral Capsules, MCLA-129, Osimertinib, PLB1001, and others.<\/li>\n<li>C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>For a detailed overview of our latest research findings and future plans, read the full details of C-MET Non-Small Cell Lung Cancer Pipeline on our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">C-MET Non-Small Cell Lung Cancer Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Collaboration Deals<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>EGF 816 (Nazartinib): Novartis<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>APL 101 (Bozitinib): Apollomics Inc.<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Pre-clinical and Discovery Stage Products<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Products<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Unmet Needs<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Market Drivers and Barriers<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Future Perspectives and Conclusion<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Analyst Views<\/li>\n<li>C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cmet-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cmet-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s,&nbsp;&ldquo;C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight 2024&rdquo;&nbsp;report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the C-MET Non-Small Cell Lung Cancer pipeline drug &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cmet-nonsmall-cell-lung-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight_704738.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-704738","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/704738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=704738"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/704738\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=704738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=704738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=704738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}